AbCellera Biologics (NasdaqGS:ABCL) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Speaker4Good afternoon, and welcome to AbCellera's full year 2025 business update conference call. My name is Chelsea, and I will facilitate the audio portion of today's interact. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. To withdraw your question, press star one again. At this time, I would like to turn ...

PresentationOperator Hello, and welcome to the Protara Therapeutics ASCO GU Update Call. [Operator Instructions] As a reminder, this conference call is being recorded. If you have any objections, please disconnect at this time. With that, I would now like to turn the call over to Justine O'Malley, Senior Vice President, Investor Relations and Corporate Affairs. ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 辽宁成大生物股份有限公司（以下简称"公司"）全资子公司成大生物（本溪）有限公司（以下简称"本 溪子公司"）于近日收到国家药品监督管理局签发的冻干人用狂犬病疫苗（人二倍体细胞）（以下简 称"人用二倍体狂犬疫苗"）《药品注册证书》。现将相关情况公告如下： 药品批准文号：国药准字S20260012 药品批准文号有效期：至2031年02月09日 上市许可持有人：成大生物（本溪）有限公司 生产企业：成大生物（本溪）有限公司 证书编号：2026S00502 一、药品基本情况 药品名称：冻干人用狂犬病疫苗（人二倍体细胞） 剂型：注射剂 规格：按标示量复溶后每瓶1.0ml。每1次人用剂量为1.0ml，狂犬病疫苗效价应不低于2.5IU。 批准事项：药品注册（境内生产） 注册分类：预防用生物制品 三、对公司的影响 辽宁成大生物股份有限公司 本次本溪子公司人用二倍体狂犬疫苗获批上市，将进一步完善公司疫苗产品布局，增强核心竞争力，巩 固在狂犬病疫苗领 ...

Tempus AI (NasdaqGS:TEM) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsCasey Woodring - VP of Equity ResearchDan Brennan - Managing DirectorElizabeth Krutoholow - VP of Investor RelationsEric Lefkofsky - CEOJames William Rogers - CFOJesse Case - Managing DirectorMark Massaro - DirectorMark Schappel - Managing DirectorSubbu Nambi - Senior Managing DirectorConference Call ParticipantsAndrew Brackmann - Equity Research AnalystBradley Bowers - Director and Senior Research AnalystCallum ...

Tempus AI (NasdaqGS:TEM) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsBradley Bowers - Managing DirectorCasey Woodring - VP of Equity ResearchDan Brennan - Managing DirectorEric Lefkofsky - CEOJames William Rogers - CFOJesse Case - Managing DirectorLiz Quattruccio - VP of Investor RelationsMark Massaro - DirectorMark Schappel - Managing DirectorSubbu Nambi - Senior Managing DirectorConference Call ParticipantsAndrew Brackmann - Equity Research AnalystColleen Kusy - Research Analys ...

Vaxcyte (NasdaqGS:PCVX) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAndrew Guggenhime - President and CFOAsad Haider - Managing DirectorDina Ramadane - Biotech Equity Research AssociateEvan Wang - VP of Equity ResearchGrant Pickering - CEOJim Wassil - EVP and COOJonathan Miller - Managing Director of Biotech and Pharma Equity ResearchMike Miletich - Chief Commercial OfficerConference Call ParticipantsCarter Gould - Managing Director and Senior AnalystJoseph Stringer - Senior Anal ...

Vaxcyte (NasdaqGS:PCVX) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAndrew Guggenhime - President and CFOAsad Haider - Managing DirectorDina Ramadane - Biotech Equity Research AssociateEvan Wang - VP, Equity ResearchGrant Pickering - CEOJim Wassil - EVP and COOJonathan Miller - Equity Research AssociateMike Miletich - Chief Commercial OfficerConference Call ParticipantsCarter Gould - Managing Director and Senior AnalystJoseph Stringer - Senior AnalystRoger Song - Senior Equity Re ...

Vaxcyte (NasdaqGS:PCVX) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker13Good afternoon. My name is Chloe. I will be your conference operator for the Vaxcyte fourth quarter and full year 2025 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer period. If you would like to ask a question during this time, simply press star followed by 1 on your telephone keypad. If you would like to ...

Tempus AI (NasdaqGS:TEM) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker12day, and thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Tempus AI Fourth Quarter 2025 Fiscal Results Conference Call. At this time, all lines are in a listen-only mode to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. We respectfully request that you limit questions to on ...

TuHURA Biosciences Announces Participation in Upcoming Investor Conferences [Accessibility Statement] Skip NavigationTAMPA, Fla., Feb. 24, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that Dr. James Bianco, President and Chief Executive Officer, will participate in the following upcoming investor conferences:Citizens Life Science Conferen ...